MOXD1

Summary

MOXD1 (monooxygenase DBH like 1, HGNC:21063) is a protein-coding gene on chromosome 6q23.2, encoding DBH-like monooxygenase protein 1 (Q6UVY6).

Predicted to enable copper ion binding activity and dopamine beta-monooxygenase activity. Predicted to be involved in dopamine catabolic process; norepinephrine biosynthetic process; and octopamine biosynthetic process. Part of endoplasmic reticulum membrane.

Source: NCBI Gene 26002 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 101 total
• MANE Select transcript: NM_015529

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21063
Approved symbol	MOXD1
Name	monooxygenase DBH like 1
Location	6q23.2
Locus type	gene with protein product
Status	Approved
Aliases	DKFZP564G202, MOX, dJ248E1.1
Ensembl gene	ENSG00000079931
Ensembl biotype	protein_coding
OMIM	609000
Entrez	26002

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 10 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000336749, ENST00000367963, ENST00000392401, ENST00000489128, ENST00000897946, ENST00000897947, ENST00000897948, ENST00000897949, ENST00000940885, ENST00000940886, ENST00000940887

RefSeq mRNA: 1 — MANE Select: NM_015529 NM_015529

CCDS: CCDS5152

Canonical transcript exons

ENST00000367963 — 12 exons

Exon	Start	End
ENSE00000763967	132328013	132328115
ENSE00000798735	132297787	132297955
ENSE00000798736	132315635	132315777
ENSE00000919221	132372830	132372997
ENSE00001014944	132372608	132372691
ENSE00001014945	132374631	132374777
ENSE00001014946	132328415	132328594
ENSE00001446002	132296055	132297317
ENSE00001906046	132401163	132401475
ENSE00003491641	132323931	132324097
ENSE00003514003	132322679	132322870
ENSE00003581619	132320629	132320688

Expression profiles

Bgee: expression breadth ubiquitous, 229 present calls, max score 98.31.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 21.4273 / max 719.4897, expressed in 1078 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
75593	20.0249	1069
75591	1.1606	530
75592	0.2418	130

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	98.31	gold quality
ganglionic eminence	UBERON:0004023	96.69	gold quality
cartilage tissue	UBERON:0002418	96.04	gold quality
periodontal ligament	UBERON:0008266	92.38	gold quality
metanephros cortex	UBERON:0010533	91.67	gold quality
gall bladder	UBERON:0002110	91.34	gold quality
body of uterus	UBERON:0009853	90.92	gold quality
stromal cell of endometrium	CL:0002255	90.43	gold quality
endometrium	UBERON:0001295	88.85	gold quality
mucosa of stomach	UBERON:0001199	88.57	gold quality
myometrium	UBERON:0001296	88.49	gold quality
left adrenal gland	UBERON:0001234	87.87	gold quality
cauda epididymis	UBERON:0004360	87.83	gold quality
left adrenal gland cortex	UBERON:0035825	87.73	gold quality
uterus	UBERON:0000995	87.16	gold quality
right adrenal gland	UBERON:0001233	86.79	gold quality
adrenal cortex	UBERON:0001235	86.78	gold quality
esophagus mucosa	UBERON:0002469	86.78	gold quality
smooth muscle tissue	UBERON:0001135	86.69	gold quality
upper lobe of left lung	UBERON:0008952	86.57	gold quality
esophagus	UBERON:0001043	86.54	gold quality
upper lobe of lung	UBERON:0008948	86.47	gold quality
lower esophagus	UBERON:0013473	86.16	gold quality
lower esophagus muscularis layer	UBERON:0035833	86.13	gold quality
right adrenal gland cortex	UBERON:0035827	86.11	gold quality
adrenal gland	UBERON:0002369	85.94	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	85.62	gold quality
embryo	UBERON:0000922	85.04	gold quality
lower esophagus mucosa	UBERON:0035834	84.31	gold quality
caudate nucleus	UBERON:0001873	83.94	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-124472	yes	479.96
E-HCAD-10	yes	68.98
E-ANND-3	yes	4.68
E-ENAD-20	no	2424.63
E-MTAB-6911	no	147.71

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

87 targeting MOXD1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-4802-3P	99.72	70.13	1273
HSA-MIR-149-3P	99.72	68.22	3963

Literature-anchored findings (GeneRIF, showing 3)

• Based on its sequence and localization, MOX (monooxygenase X) is predicted to hydroxylate a hydrophobic substrate in the endoplasmic reticulum. (PMID:15337741)
• RNA N6-methyladenosine demethylase FTO targets MOXD1 promoting the malignant phenotype of gastric cancer. (PMID:38200441)
• MOXD1 is a lineage-specific gene and a tumor suppressor in neuroblastoma. (PMID:38905335)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	moxd1	ENSDARG00000031136
mus_musculus	Moxd1	ENSMUSG00000020000
rattus_norvegicus	Moxd1	ENSRNOG00000015321
drosophila_melanogaster	CG5235	FBGN0036565
drosophila_melanogaster	olf413	FBGN0037153

Paralogs (1): DBH (ENSG00000123454)

Protein

Protein identifiers

DBH-like monooxygenase protein 1 — Q6UVY6 (reviewed: Q6UVY6)

Alternative names: Monooxygenase X

All UniProt accessions (2): Q6UVY6, A6PVS1

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Endoplasmic reticulum membrane.

Tissue specificity. Highly expressed in lung, kidney, brain and spinal cord.

Post-translational modifications. N-glycosylated.

Cofactor. Binds 2 copper ions per subunit.

Induction. By replicative senescence.

Miscellaneous. Major.

Similarity. Belongs to the copper type II ascorbate-dependent monooxygenase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q6UVY6-1	1, Long	yes
Q6UVY6-2	2, Short

RefSeq proteins (1): NP_056344* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000323	Cu2_ascorb_mOase_N	Domain
IPR000945	DBH-like	Family
IPR005018	DOMON_domain	Domain
IPR008977	PHM/PNGase_F_dom_sf	Homologous_superfamily
IPR014784	Cu2_ascorb_mOase-like_C	Homologous_superfamily
IPR024548	Cu2_monoox_C	Domain
IPR028460	Tbh/DBH	Family
IPR036939	Cu2_ascorb_mOase_N_sf	Homologous_superfamily
IPR045266	DOH_DOMON	Domain

Pfam: PF01082, PF03351, PF03712

UniProt features (29 total): binding site 6, disulfide bond 5, glycosylation site 4, sequence conflict 3, splice variant 2, sequence variant 2, active site 2, signal peptide 1, chain 1, topological domain 1, transmembrane region 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6UVY6-F1	89.34	0.75

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 203; 389

Ligand- & substrate-binding residues (6): 389; 391; 464; 235; 236; 307

Disulfide bonds (5): 205–257, 242–269, 364–480, 368–550, 443–465

Glycosylation sites (4): 114, 247, 476, 517

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 160 (showing top): GOBP_PHENOL_CONTAINING_COMPOUND_METABOLIC_PROCESS, GOBP_PHENOL_CONTAINING_COMPOUND_BIOSYNTHETIC_PROCESS, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, GOCC_SECRETORY_GRANULE, PEREZ_TP63_TARGETS, CHANDRAN_METASTASIS_DN, BOHN_PRIMARY_IMMUNODEFICIENCY_SYNDROM_DN, BROWNE_HCMV_INFECTION_48HR_DN, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, GOBP_DOPAMINE_METABOLIC_PROCESS, RIGGI_EWING_SARCOMA_PROGENITOR_DN, ONDER_CDH1_TARGETS_2_UP, VANHARANTA_UTERINE_FIBROID_DN, RICKMAN_HEAD_AND_NECK_CANCER_A, AACTTT_UNKNOWN

GO Biological Process (3): octopamine biosynthetic process (GO:0006589), dopamine catabolic process (GO:0042420), norepinephrine biosynthetic process (GO:0042421)

GO Molecular Function (8): dopamine beta-monooxygenase activity (GO:0004500), copper ion binding (GO:0005507), catalytic activity (GO:0003824), monooxygenase activity (GO:0004497), protein binding (GO:0005515), oxidoreductase activity (GO:0016491), oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced ascorbate as one donor, and incorporation of one atom of oxygen (GO:0016715), metal ion binding (GO:0046872)

GO Cellular Component (5): obsolete extracellular space (GO:0005615), endoplasmic reticulum membrane (GO:0005789), secretory granule membrane (GO:0030667), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
biogenic amine biosynthetic process	1
alcohol biosynthetic process	1
phenol-containing compound biosynthetic process	1
octopamine metabolic process	1
dopamine metabolic process	1
catecholamine catabolic process	1
norepinephrine metabolic process	1
catecholamine biosynthetic process	1
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced ascorbate as one donor, and incorporation of one atom of oxygen	1
transition metal ion binding	1
molecular_function	1
oxidoreductase activity	1
binding	1
catalytic activity	1
monooxygenase activity	1
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	1
cation binding	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
secretory granule	1
cytoplasmic vesicle membrane	1
bounding membrane of organelle	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

946 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MOXD1	TAAR5	O14804	905
MOXD1	STX7	O15400	859
MOXD1	TAAR6	Q96RI8	757
MOXD1	CPLX3	Q8WVH0	548
MOXD1	PF4	P02776	447
MOXD1	SRXN1	Q9BYN0	447
MOXD1	SLC18B1	Q6NT16	439
MOXD1	HMOX1	P09601	432
MOXD1	TMEM163	Q8TC26	431
MOXD1	HOPX	Q9BPY8	425
MOXD1	NCF1	P14598	418
MOXD1	UBD	O15205	418
MOXD1	CYBA	P13498	415
MOXD1	LIX1	Q8N485	410
MOXD1	FYN	P06241	409

IntAct

61 interactions, top by confidence:

A	B	Type	Score
GLRX3	MOXD1	psi-mi:“MI:0915”(physical association)	0.780
MOXD1	GLRX3	psi-mi:“MI:0915”(physical association)	0.780
C1QTNF9	C1QTNF9B	psi-mi:“MI:0914”(association)	0.780
MOXD1	GPAA1	psi-mi:“MI:0914”(association)	0.620
MOXD1	GPAA1	psi-mi:“MI:0915”(physical association)	0.620
SCGB1D1	FAM234B	psi-mi:“MI:0914”(association)	0.530
DEFA1	MANBA	psi-mi:“MI:0914”(association)	0.530
TAFA4	NRP1	psi-mi:“MI:0914”(association)	0.530
CMA1	MANBA	psi-mi:“MI:0914”(association)	0.530
CTSG	MANBA	psi-mi:“MI:0914”(association)	0.530
DNAJC3	DEDD	psi-mi:“MI:0914”(association)	0.530
ACACB	MOXD1	psi-mi:“MI:0915”(physical association)	0.400
GPC1	SNAP23	psi-mi:“MI:0915”(physical association)	0.400
GPC1	GANAB	psi-mi:“MI:0915”(physical association)	0.400
CSNK2B	MOXD1	psi-mi:“MI:0915”(physical association)	0.370
TRAF2	UMAD1	psi-mi:“MI:0914”(association)	0.350
RBCK1	UMAD1	psi-mi:“MI:0914”(association)	0.350
SHARPIN	MAP3K7	psi-mi:“MI:0914”(association)	0.350
TANK	CNOT1	psi-mi:“MI:0914”(association)	0.350
TNIP2	CHUK	psi-mi:“MI:0914”(association)	0.350
TRAF2	TMEM178B	psi-mi:“MI:0914”(association)	0.350
RBCK1	KHNYN	psi-mi:“MI:0914”(association)	0.350
SHARPIN	UMAD1	psi-mi:“MI:0914”(association)	0.350
TNIP1	COCH	psi-mi:“MI:0914”(association)	0.350
TNIP2	TMEM178B	psi-mi:“MI:0914”(association)	0.350

BioGRID (68): MOXD1 (Two-hybrid), MOXD1 (Affinity Capture-MS), MOXD1 (Affinity Capture-MS), MOXD1 (Affinity Capture-MS), MOXD1 (Affinity Capture-MS), MOXD1 (Affinity Capture-MS), MOXD1 (Affinity Capture-MS), MOXD1 (Affinity Capture-MS), MOXD1 (Affinity Capture-MS), MOXD1 (Affinity Capture-MS), MOXD1 (Affinity Capture-MS), MOXD1 (Affinity Capture-MS), MOXD1 (Affinity Capture-MS), MOXD1 (Affinity Capture-MS), GPAA1 (Affinity Capture-MS)

ESM2 similar proteins: A0A2D0TC04, A2VDP5, B0BND0, F1N5C8, J3SBP3, J3SEZ3, O14638, O62806, O94323, P06802, P0DQQ4, P23188, P23377, P29119, P54793, P70699, P84039, P97675, Q0VA77, Q29444, Q32KH8, Q4FZV0, Q566N0, Q58D68, Q5BKW7, Q5FYA8, Q5R5M5, Q5RAC0, Q5RB45, Q6AX80, Q6DDP3, Q6DYE8, Q6P179, Q6P7A9, Q6UVY6, Q6UWR7, Q8BGN3, Q8BTJ4, Q8C129, Q8IVL8

Diamond homologs: A6NHM9, P09172, P15101, Q05754, Q08CS6, Q5TZ24, Q64237, Q68CI2, Q6UVY6, Q7TT41, Q86B61, Q98ST7, Q9CXI3, Q9XTA0, Q61P40, Q9VUY0, Q9XTQ6, Q6NP60, P08478

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 81 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
TNFR1-induced NF-kappa-B signaling pathway	5	32.3×	1e-04
Neutrophil degranulation	10	4.4×	7e-03

GO biological processes:

GO term	Partners	Fold	FDR
canonical NF-kappaB signal transduction	6	32.3×	2e-05
negative regulation of canonical NF-kappaB signal transduction	6	15.2×	4e-04
positive regulation of canonical NF-kappaB signal transduction	7	7.5×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

101 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	93
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2035 predictions. Top by Δscore:

Variant	Effect	Δscore
6:132297785:A:AC	donor_gain	1.0000
6:132297786:C:CC	donor_gain	1.0000
6:132297956:C:CC	acceptor_gain	1.0000
6:132315633:A:AC	donor_gain	1.0000
6:132315634:C:CC	donor_gain	1.0000
6:132315634:CGTGA:C	donor_gain	1.0000
6:132315776:CC:C	acceptor_gain	1.0000
6:132315777:CC:C	acceptor_gain	1.0000
6:132320627:A:AC	donor_gain	1.0000
6:132320627:AC:A	donor_gain	1.0000
6:132320628:C:CC	donor_gain	1.0000
6:132320628:CC:C	donor_gain	1.0000
6:132320684:TCTCC:T	acceptor_gain	1.0000
6:132320685:CTCC:C	acceptor_gain	1.0000
6:132320685:CTCCC:C	acceptor_gain	1.0000
6:132320686:TCCCT:T	acceptor_gain	1.0000
6:132320687:CC:C	acceptor_gain	1.0000
6:132320687:CCCT:C	acceptor_loss	1.0000
6:132320688:CC:C	acceptor_gain	1.0000
6:132320689:C:A	acceptor_loss	1.0000
6:132320690:TGAAA:T	acceptor_loss	1.0000
6:132322677:A:AC	donor_gain	1.0000
6:132322678:C:CC	donor_gain	1.0000
6:132322698:T:TA	donor_gain	1.0000
6:132322699:C:A	donor_gain	1.0000
6:132322712:AAACT:A	donor_gain	1.0000
6:132322768:T:TA	donor_gain	1.0000
6:132322769:C:A	donor_gain	1.0000
6:132328444:CAGTT:C	donor_gain	1.0000
6:132372828:A:AC	donor_gain	1.0000

AlphaMissense

4057 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:132315697:A:C	S482R	0.999
6:132315697:A:T	S482R	0.999
6:132315699:T:G	S482R	0.999
6:132297815:C:G	C550S	0.998
6:132297816:A:T	C550S	0.998
6:132297877:C:A	W529C	0.998
6:132297877:C:G	W529C	0.998
6:132315703:A:C	C480W	0.998
6:132315705:A:G	C480R	0.998
6:132315748:A:C	C465W	0.998
6:132320678:A:G	L439P	0.998
6:132323952:G:C	C364W	0.998
6:132323953:C:T	C364Y	0.998
6:132328452:C:T	C269Y	0.998
6:132297790:C:A	W558C	0.997
6:132297790:C:G	W558C	0.997
6:132297816:A:G	C550R	0.997
6:132297949:C:A	W505C	0.997
6:132297949:C:G	W505C	0.997
6:132315704:C:G	C480S	0.997
6:132315704:C:T	C480Y	0.997
6:132315705:A:T	C480S	0.997
6:132315749:C:G	C465S	0.997
6:132315750:A:G	C465R	0.997
6:132315750:A:T	C465S	0.997
6:132320666:C:G	C443S	0.997
6:132320667:A:T	C443S	0.997
6:132323942:A:G	C368R	0.997
6:132323954:A:G	C364R	0.997
6:132324006:G:C	S346R	0.997

dbSNP variants (sampled 300 via entrez): RS1000000881 (6:132333063 G>A), RS1000012224 (6:132356731 C>A,T), RS1000027647 (6:132338426 A>T), RS1000067716 (6:132392563 G>T), RS1000080956 (6:132350577 T>C), RS1000131609 (6:132311506 T>C), RS1000174829 (6:132341211 G>A), RS1000199166 (6:132304167 A>G), RS1000237390 (6:132308865 T>C), RS1000242286 (6:132355643 C>T), RS1000270916 (6:132399745 C>G), RS1000348297 (6:132304465 G>A,T), RS1000361805 (6:132321186 C>G,T), RS1000385926 (6:132386781 A>C,G), RS1000423501 (6:132386428 C>A)

Disease associations

OMIM: gene MIM:609000 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST001762_459	Obesity-related traits	2.000000e-06
GCST001762_533	Obesity-related traits	2.000000e-06
GCST001762_539	Obesity-related traits	5.000000e-06
GCST001762_583	Obesity-related traits	9.000000e-06
GCST001762_615	Obesity-related traits	1.000000e-07
GCST001762_681	Obesity-related traits	1.000000e-06
GCST001762_89	Obesity-related traits	1.000000e-07
GCST008839_579	Height	3.000000e-10

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0005109	energy expenditure
EFO:0004887	maximal oxygen uptake measurement
EFO:0004338	body weight
EFO:0005106	body composition measurement
EFO:0004995	lean body mass

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression, affects cotreatment	7
Arsenic	decreases expression, increases abundance, affects cotreatment	3
Benzo(a)pyrene	affects methylation, increases expression	2
Cadmium	increases palmitoylation, increases expression, decreases reaction, increases abundance	2
Cadmium Chloride	increases palmitoylation, increases expression, decreases reaction, increases abundance	2
aristolochic acid I	decreases expression	1
GSK-J4	increases expression	1
propionaldehyde	increases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
sodium arsenate	increases abundance, decreases expression	1
terbufos	increases methylation	1
trichostatin A	decreases expression	1
arsenite	increases methylation	1
sulforaphane	decreases expression	1
sodium arsenite	affects cotreatment, decreases expression, increases abundance	1
butyraldehyde	increases expression	1
2-bromopalmitate	decreases reaction, increases abundance, increases palmitoylation	1
manganese chloride	increases abundance, affects cotreatment, decreases expression	1
nickel sulfate	increases expression	1
pentanal	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
quinocetone	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	decreases expression, affects cotreatment	1
incobotulinumtoxinA	increases expression	1
Zoledronic Acid	increases expression	1
Vorinostat	decreases expression	1
Acetaminophen	increases expression	1
Aldehydes	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.